Where Medical Device Marketing Strategy Fails Post-Clearance

A marketing strategy for medical devices is a market engineering problem, not a campaign planning problem. Most medtech founders arrive at commercialization with FDA clearance, clinical validation, and physician champions who trust the device.

Revenue stalls anyway. Procurement won't move. Investors ask for more traction.

The device works. But the market hasn't been engineered to receive it. That gap needs a different framework entirely.

Key Takeaways

• FDA clearance opens the legal right to sell. Market clearance has to be engineered separately, and most medical device marketing strategies skip that step entirely.
• Axonics engineered a $3.7B exit not by running campaigns but by treating their medical device marketing strategy as a market engineering problem from day one.
• The traction gap sits between initial product release and minimum viable traction. Campaign spend doesn't close it. Category design does.
• Market-product fit, not product-market fit, is the correct sequence. Engineer a market that sees your solution as inevitable before you scale your commercial team.
• A marketing strategy for medical devices that builds commercial infrastructure has five components: category design, market narrative, clinical-to-commercial bridge, pull-driven demand architecture, and measurement systems tied to market development.
• Commercialization in medtech requires four legs: product engineering, regulatory, market access and reimbursement, and market engineering. Most founders invest in three and wonder why revenue stalls.

Why Standard Marketing Strategy Templates Break Down in Medtech Commercialization

Every business school marketing framework starts with the same assumption, that a market exists and your job is to reach it.

That assumption breaks in medtech.

When I talk to pre-traction founders on The State of MedTech, the pattern is consistent. They've just cleared 510(k). They've completed a successful clinical study. They have three physician champions who trust the device. And they are completely unprepared for what comes next.

Because FDA clearance is the starting line, not the finish line. It gives you the legal right to sell into a hospital system. It tells procurement nothing about whether your device fits their existing protocols, their reimbursement structure, or their budget cycle.

The market engineering framework at MarketCraft starts here, with a structural diagnosis of why the gap exists.

I covered this on a recent episode about market engineering for medtech startups:

The traction gap is a space between building a product and achieving real, repeatable traction. There's a lot of discipline around engineering and developing your product. There's not a lot of discipline and engineering when it comes to thinking about a market.

Most medtech founders switch from rigorous product engineering to improvising everything about their category, their messaging, and their narrative. There's no framework on the shelf for building a market itself.

So they reach for the tools they know: a website, conference presence, a few KOL relationships. None of it compounds into commercial traction.

The standard marketing strategy template, built for software companies or consumer brands, assumes pull already exists in the market. In medtech, you build that pull first. That's why medtech commercialization strategy requires a different starting point.

How Market Engineering Differs From a Standard Medical Device Campaign Strategy

Campaign strategy asks: who is my audience and how do I reach them?

Market engineering asks: what does the market need to believe before it can buy?

These are different questions with different answers and different investment profiles.

I discussed this reframe on an episode about how mini strategics are winning $100B exits:

I think there's too much focus put on product market fit. What you want to think about here is market product fit. You're engineering and crafting a market that sees your solution as inevitable.

Market-product fit means the market is ready for your device because you engineered it to be. The ecosystem understands the problem category. The reimbursement pathway is mapped. The KOL network is activated. The clinical evidence is framed to drive adoption, not just to satisfy a regulatory body.

This is what separates the medical device marketing strategies that build infrastructure from the ones that burn runway chasing clicks.

The companies that win, the Axonics, the THINK Surgicals, the Shockwave Medicals, didn't wait for a market to form around their technology. They engineered it. They crafted a category narrative. They designed a minimum viable category that pulled the right buyers toward them before they scaled a full sales team.

That's the foundational difference. And it changes everything about how you sequence your marketing investment.

The Three Stages of a Medical Device Marketing Strategy That Creates Commercial Traction

Not all medtech companies need the same marketing strategy. The right inputs depend on where you are in your commercialization arc.

Pre-traction. You have FDA clearance and early clinical validation. Revenue is minimal or zero. Your job here is category design and market narrative. You're not trying to close 100 accounts. You're engineering the belief system that makes closing those accounts possible. You need a clear minimum viable category, a market narrative that frames why your solution is inevitable, and an ICP narrow enough to be winnable.

At traction. You have repeatable revenue from a defined customer cohort. Your job now is to build repeatable systems. I covered this on an episode about how medtech startups cross the chasm:

The way you cross the chasm is through focus. You don't win the whole market. You win a small segment at first. You have repeatable systems, repeatable sales, you have a very clear ideal customer profile or ICP and you have a defined use case.

At traction, the medical device marketing strategy shifts from belief-building to system-building. You're not writing new categories. You're turning the category you engineered into predictable revenue.

Post-traction. You have 15 to 18 percent market share or better. The medical device go-to-market strategy from this stage is about crossing the chasm into the mainstream market. You're scaling the systems you built, not rebuilding the category. Pull-driven demand should be working. Your job is to accelerate it.

Most medtech founders try to apply post-traction tactics at pre-traction stages. They hire sales reps before the category is defined. They run campaigns before the market narrative is clear. That's where runway disappears.

The Five Components of a Marketing Strategy for Medical Devices That Builds Infrastructure

A medical device marketing strategy that builds commercial infrastructure has five components. They stack in sequence.

Category design. Before anything else, you define the category your device creates or dominates. This is category design for medtech, and it starts with a category narrative: why does this problem category exist, why does it matter now, and why is your device the inevitable solution? Without this, you're a feature competing against other features.

Market narrative. A market narrative is not a tagline. It's the belief architecture the market needs to adopt before it will buy from you. It answers: what does a hospital system, an IDN, or a surgery center need to believe to see your device as a priority acquisition? Your market narrative drives KOL activation, investor conviction, and sales rep messaging.

Clinical-to-commercial bridge. Clinical validation and commercial traction are separate things. Clinical evidence proves the device works. The clinical-to-commercial bridge translates that evidence into commercial language, including reimbursement narratives, outcomes data framed for procurement, and economic models that fit a hospital CFO's decision framework.

Pull-driven demand architecture. Push-driven demand means you're hunting for every account. Pull-driven demand means accounts find you because the category narrative has done the persuasion work upstream. Henry Peck, a medtech startup veteran, captured this structure on an episode about accelerating your medtech career:

While engineering and fantastic product is at the center of it, it doesn't work without the other legs of the stool: the commercialization, the regulatory, the market access and reimbursement.

Pull-driven demand is what happens when your market narrative, your category design, and your clinical-to-commercial bridge are aligned and reinforcing each other.

Measurement systems. Most medtech marketing measurement is built for campaign performance, clicks, impressions, open rates. But campaign metrics don't tell you whether the market is developing. You need market development metrics: category awareness in your target ICP, reimbursement coverage depth, KOL engagement velocity, and sales cycle compression over time.

How to Sequence Your Medical Device Marketing Investment Before Runway Runs Out

The sequencing error I see most often: founders invest in sales capacity before the category is defined.

They hire five reps, give them a product deck, and send them into accounts where no one has heard of the category. The reps get lost.

The pipeline stalls. The board asks why sales isn't working. And the answer is that you tried to sell into a market you hadn't engineered yet.

The right sequence is: category design, then market narrative, then clinical-to-commercial bridge, then pull-driven demand architecture, then sales capacity expansion. Build the belief before you build the team.

On a solo episode I recorded about attention and market engineering, I covered the discipline this requires:

You got to decide what the market wants to notice. How do you engineer and craft that message around that market? And then repeat it until the perception crystallizes.

That last part matters. Perception crystallizes over time. It requires message consistency, repeated presence in the right channels, and the discipline to hold your market narrative without changing it. Most marketing failure in medtech isn't a creativity failure. It's a consistency failure.

The founders who win engineer their market first. Then they scale into it.

What This Means for Medtech Founders

In my experience working with medtech founders at MarketCraft, the most common mistake isn't a bad product or a bad team. The mistake is applying a software-era marketing strategy to a medtech commercialization problem.

Software companies can afford to test and iterate on audience and messaging because distribution is cheap. In medtech, a wrong sequencing decision costs you 12 months of runway and a confused sales team.

If I could give one reframe to every pre-traction medtech founder: your marketing strategy for medical devices has to answer "what does the market need to believe?" before it answers "how do we reach the market?"

Clinical validation tells you the device works. Market engineering tells the market why it matters, who it's for, and why now is the right time to adopt it. Those are two separate workstreams, and most early-stage medtech companies only fund one.

The ones that win fund both from the beginning.

If you're in the pre-traction stage and still building your market narrative or defining your category, the market engineering framework and category design for medtech posts give you the full architecture.

If you're at traction and trying to cross the chasm, the medtech commercialization strategy post covers what to do next.

Frequently Asked Questions

What is a marketing strategy for medical devices?

A marketing strategy for medical devices is a market engineering framework, not a campaign plan. It includes category design, market narrative development, clinical-to-commercial translation, pull-driven demand architecture, and measurement systems tied to market development.

Because medical device buyers follow procurement protocols, reimbursement structures, and clinical validation requirements, the strategy has to address all four legs of commercialization: product, regulatory, market access, and market engineering.

How is marketing strategy for medical devices different from other B2B marketing?

In most B2B markets, a market already exists and your job is to reach buyers. In medtech, you often have to engineer the market before buyers can recognize the need for your device.

FDA clearance gives legal permission to sell. Market clearance, the moment when a hospital system sees your device as a priority acquisition, has to be built separately through category design, KOL activation, reimbursement pathway development, and market narrative.

What are the components of an effective medical device marketing strategy?

An effective medical device marketing strategy has five components: category design (defining the problem space your device owns), market narrative (the belief architecture the market needs to adopt), clinical-to-commercial bridge (translating clinical evidence into economic and procurement language), pull-driven demand architecture (building inbound attention from the right buyers), and market development measurement. These stack in sequence and each one enables the next.

How do you build a marketing strategy for a pre-traction medical device company?

Start with category design before you invest in commercial capacity. Define your minimum viable category: who is the ICP, what is the use case, and what does the market need to believe to see your device as inevitable?

Build a market narrative that activates that belief across your KOL network, investor conversations, and commercial channels. Hire sales reps after the category is defined, not before, or you'll spend runway educating a market that hasn't been prepared to buy.

Listen to the Full Conversations

The episodes referenced in this post are available on The State of MedTech:

• How Market Engineering Helps Medtech Startups Raise Capital (April 15, 2026)
• $100B Exit Fix: How Mini Strategics Are Winning (January 5, 2026)
• How Medtech Startups Drive Technology Adoption to Cross the Chasm (April 22, 2026)
• How to Accelerate Your Career Growth in Medtech with Henry Peck (February 12, 2025)
• Chamath Was Right: Attention Is the Operating System of AI, Media, and Markets (May 14, 2026)

Subscribe wherever you listen to podcasts.

About the Author

Omar Khateeb is the founder of MarketCraft and host of The State of MedTech, the number one podcast in the medtech industry.

He works with medtech founders and commercial leaders on market engineering, commercialization strategy, and revenue growth. Visit marketcraft.ai or subscribe to The State of MedTech for weekly conversations with the people building the future of medical devices.